17x Return on DOJ Fraud


Fraud and abuse has been a hot topic for Congressional oversight, and the DOJ is performing admirably by stockpiling revenues — $2.5B in FY2010 alone for civil healthcare fraud with $1.6MM courtesy of pharma and medical device companies.  Additionally, with the DOJ’s outstanding returns, $17 for every dollar spent on enforcement from FY2007-FY2009 (check out page 31 of their appropriations report), the DOJ’s ROI looks better than most pharma and medical device companies.

If you have been wondering when the right time was to learn more about compliance, the laws and enforcement, the time is now.

Many thanks to the bright minds at McDermott Will & Emery for presenting these numbers at the eye-opening AdvaMed/MTLI Fraud and Abuse course.

To keep up with the best in Good Promotional Practices, subscribe to our GPP RSS feed, our Facebook page, our Twitter stream or our LinkedIn group.

One response to “17x Return on DOJ Fraud

  1. Pingback: Pharma Petitions FDA for Binding Off-Label Rules | Good Promotional Practices

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s